N-(1-pyridin-2-ylethoxy)phthalimide | 1034621-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-(1-pyridin-2-ylethoxy)phthalimide
• 英文别名: 2-[1-(2-Pyridinyl)ethoxy]-1H-isoindole-1,3(2H)-dione；2-(1-pyridin-2-ylethoxy)isoindole-1,3-dione
• CAS: 1034621-80-1
• 化学式: C₁₅H₁₂N₂O₃
• 分子量: 268.272
• InChiKey: PPDLRLGMJAAZJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  59.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-乙基吡啶 、 N-羟基邻苯二甲酰亚胺 在 碘苯二乙酸 、 copper(l) chloride 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以69%的产率得到N-(1-pyridin-2-ylethoxy)phthalimide
  参考文献：
  名称：

  Cu-Facilitated C−O Bond Formation Using N-Hydroxyphthalimide: Efficient and Selective Functionalization of Benzyl and Allylic C−H Bonds

  摘要：

  A highly efficient protocol for the benzyl or allylic C-H functionalization of simple hydrocarbons has been developed using stoichiometric amounts of N-hydroxyphthalimide and Phl(OAc)(2) in the presence of CuCl catalyst. The reaction was revealed to proceed via a radical pathway, in which phthalimide N-oxyl (PINO) radical plays a dual role, serving as a catalytic hydrogen abstractor from hydrocarbons as well as a stoichiometric reagent to couple with the resultant alkyl radicals.

  DOI：

  10.1021/ja8031218

文献信息

• TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF
  申请人：Hisamichi Hiroyuki

  公开号：US20100227866A1

  公开（公告）日：2010-09-09

  [Problems] To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). [Means for Solving Problems] It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

  [问题] 提供一种药物，特别是一种可用作治疗肠易激综合征（IBS）的治疗剂。 [解决问题的方法] 发现一种在4位具有酰胺基团或其药学上可接受的盐的四氢异喹啉-1-酮衍生物具有优异的肽释放因子2（BB2）受体拮抗作用。还发现四氢异喹啉-1-酮衍生物对肠道运动障碍非常有效。由此可见，本发明的四氢异喹啉-1-酮衍生物对与BB2受体相关的疾病，特别是IBS，具有治疗剂的用途。
• Tetrahydroisoquinolin-1-one derivative or salt thereof
  申请人：Seldar Pharma Inc.

  公开号：US10016410B2

  公开（公告）日：2018-07-10

  To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

  提供一种药物，特别是一种可用作肠易激综合征（IBS）治疗剂的化合物。研究发现，一种在 4 位具有酰胺基团的四氢异喹啉-1-酮衍生物或其药学上可接受的盐具有很好的蚕豆素 2（BB2）受体拮抗作用。研究还发现，四氢异喹啉-1-酮衍生物对肠道运动障碍也有很好的疗效。综上所述，本发明的四氢异喹啉-1-酮衍生物可作为一种治疗剂，用于治疗与 BB2 受体相关的疾病，特别是肠易激综合征。
• US8486970B2
  申请人：——

  公开号：US8486970B2

  公开（公告）日：2013-07-16
• US9150541B2
  申请人：——

  公开号：US9150541B2

  公开（公告）日：2015-10-06
• US9526719B2
  申请人：——

  公开号：US9526719B2

  公开（公告）日：2016-12-27